Sign in

CIK 0001626971

  • Non-accelerated filer
  • Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464670809
Phone
+1 650-900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 5 Insider Annual Insider Trading Report
  3. 5 Insider Annual Insider Trading Report
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market buy Director bought 1,000 shares at an average $12.98 ($12,983)
  11. 4 Open-market buy Director bought 1,000 shares at an average $12.98 ($12,983)
  12. 4 Open-market buy Director bought 38,383 shares at an average $12.75 ($489,192)
  13. 4 Open-market buy Director bought 38,383 shares at an average $12.75 ($489,192)
  14. 4 Open-market buy Director bought 20,000 shares at an average $12.35 ($247,000)
  15. 4 Open-market buy Director bought 20,000 shares at an average $12.35 ($247,000)
  16. 4 Open-market buy Director bought 50,000 shares at an average $12.96 ($648,100)
  17. 4 Open-market buy Director bought 50,000 shares at an average $12.96 ($648,100)
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 4 Open-market buy Director bought 4,716 shares at $13.09 ($61,732)

Page 11 of 13 · 252 filings